Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen CoFRA:REG +0.28%41 Earnings Yield (Joel Greenblatt) % is 2.14% as of Dec. 2025. GuruFocus rates FRA:REG with a GF Score™ of 41/100 and a GF Value™ of €22.39 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,320 Biotechnology companies, RemeGen Co ranks better than 83.41% on this metric.
RemeGen Co's Enterprise Value for the quarter that ended in Dec. 2025 was €4,489.3 Mil.
RemeGen Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €144.2 Mil. RemeGen Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 2.14%.
The historical rank and industry rank for RemeGen Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:REG'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -22.5 Med: -4.97 Max: 2.42
Current: 1.97
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of RemeGen Co was 2.42%. The lowest was -22.50%. And the median was -4.97%.
FRA:REG's Earnings Yield (Joel Greenblatt) % is ranked better than 83.41% of 1320
companies
in the Biotechnology industry
Industry Median: -10.16
vs FRA:REG: 1.97
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. RemeGen Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
RemeGen Co (FRA:REG) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
RemeGen Co Earnings Yield (Joel Greenblatt) % Related Terms
RemeGen Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, RemeGen Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Earnings Yield (Joel Greenblatt) % falls into.
RemeGen Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
RemeGen Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
RemeGen Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €144.2 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 2.14% mean?
RemeGen Co (FRA:REG) has a Earnings Yield (Joel Greenblatt) % of 2.14% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #219 out of 1320 companies in the Biotechnology industry, placing it in the top 16.6%.
Is RemeGen Co's Earnings Yield (Joel Greenblatt) % too high?
RemeGen Co's current Earnings Yield (Joel Greenblatt) % is 2.14%. Based on the distribution chart, RemeGen Co ranks #219 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #219 out of 1320 companies for Earnings Yield (Joel Greenblatt) %. This places RemeGen Co in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on RemeGen Co and its competitors. RemeGen Co's current Earnings Yield (Joel Greenblatt) % is 2.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €22.39, compared to a current price of €9.32 — trading 58.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 2.14%. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Earnings Yield (Joel Greenblatt) % is 2.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.32 is trading 58.4% below its estimated GF Value™ of €22.39.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Earnings Yield (Joel Greenblatt) %: 2.14%
GF Value™: €22.39 vs. price of €9.32 (58.4% below fair value)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for FRA:REG
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
